Slide 1: Caplin Point Laboratories Ltd. Investor Presentation August 2022
Annexure - 3 A Caplin Point ~ Laboratories Limited Caplin Point Laboratories Ltd. Investor Presentation August 2022 Rated #1 in India for “Most Consistent Profitable Growth across the last 10 years”# Second Largest wealth creator for the decade ending 2020* #Value Research magazine – Wealth Insight
Slide 2: Disclaimer
Disclaimer ._. Caplin Point V ------------------------------------------------------------- Laboratories Limited The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general inform
Slide 3: Content
Caplin Point --------------• Laboratories Limited Content 1 Q1FY23 Highlights 2 Understanding Caplin 3 Growth engines of Caplin 4 More about Caplin Headquarters, Chennai 3
Slide 4: Content: Q1FY23 Highlights
._. Caplin Point V ----------------------------------------------------------- Laboratories Limited Content 1 Q1FY23 Highlights 1.1 Q1FY23 Highlights 1.2 Update on CAPEX Robust revenue growth coupled with stable 1.3 margins 1.4 P&L for the Quarter 2 Understanding Caplin 3 Growth engines of Caplin 4
Slide 5: Q1FY23 Highlights
Q1FY23 Highlights Financial Highlights • Total Revenue of Rs 360.27 Cr for Q1FY23, registered a growth of 16.3% over Q1FY22. Gross Margins stable at ~ 55% in Q1FY23 • PAT increased by 20.7% to Rs. 86.31 Cr in Q1FY23 against Rs. 71.53 Cr in Q1FY22 • Basic EPS grew by 20% to Rs. 11.21 in Q1FY23 agains
Slide 6: Q1FY23 Highlights (Cont'd)
Q1FY23 Highlights (Cont’d) ._. Caplin Point V ------------------------------------------------------------- Laboratories Limited US & Regulated Markets Business Highlights • Caplin Steriles’ (CSL) operating revenue grows 61% YoY to Rs. 41.14 Cr, with a healthy mix of Products, Milestone and Profit S
Slide 7: Update on CAPEX
Update on CAPEX ._. Caplin Point V ------------------------------------------------------------- Laboratories Limited Caplin is venturing on a Capex journey of INR ~430-450 Cr. to expand existing capacities, widen its product portfolio and backward integrate majority of the products Capacity expansi
Slide 8: Q1FY23 - Robust revenue growth coupled with stable margins
Q1FY23 - Robust revenue growth coupled with stable margins __________________________________________________ ._. Caplin Point v Laboratorieslimited Total Revenue (INR Cr) EBITDA (INR Cr) PAT (INR Cr) 86 360 116 102 72 Q1 FY23 310 Q1FY22 Q1FY23 Q1FY22 Q1FY23 Q1FY22 Q1FY23 8
Slide 9: P&L for the Quarter – Consolidated
P&L for the Quarter – Consolidated ._. Caplin Point V ------------------------------------------------------------- Laboratories Limited Value (INR Cr) Q1 FY23 Q1 FY22 YoY (%) Q4 FY22 QoQ (%) Revenue from Operation 346.33 300.44 15.3% 339.24 2.1% Other Income 13.94 9.21 11.51 Total Revenue 360.27 30
Slide 10: Content: Understanding Caplin
._. Caplin Point V --------------- Laboratories Limited Content 1 Q1FY23 Highlights 2 Understanding Caplin 2.1 Transformation across the decades 2.2 Caplin’s core business Diversified Product Portfolio with a balanced 2.3 product mix Smart mix of manufacturing and outsourcing; 2.4 Product capacities
Slide 11: Transformation across the decades
Transformation across the decades ._. Caplin Point V ------------------------------------------------- Laboratories Limited Started first commercial Started outsourcing from Work on Injectable unit shipments to US China starts Listed on Stock ' Exchange Entered Angola with Liquid injectable facility
Slide 12: Our core business – Tapping the untapped markets
Our core business – Tapping the untapped markets ._. Caplin P~i_n~ V Laboratories L1m1te Generics and Branded Generics Injectable & Ophthalmic Manufacturing and Export Revenue by Business Segment (Emerging Markets) Generic Branded Generic 75% 25% US Revenue 10%* ~35% Export ~70% Export Headquarters
Slide 13: Diversified Product Portfolio with a changing product mix
Diversified Product Portfolio with a changing product mix ._. Caplin Point V ----------------------------------------------- Laboratories Limited Diversified Product Portfolio with zero reliance on single product / Therapy 650+ Pharmaceutical formulations 36 Therapeutic Segments Latest focus towards
Slide 14: Smart mix of manufacturing, outsourcing; product capacities
Smart mix of manufacturing, outsourcing; product capacities ._. Caplin Point V ------------------------------------------------------------------------------------- Laboratories Limited r - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Slide 15: Research & Development Capabilities
Research & Development Capabilities ._. Caplin Point V ------------------------------------------------------------- Laboratories Limited 5 Dedicated Facilities INR 355 Cr Capex R&D Expense API Caplin has 5 dedicated R&D setups (3 Continuous capex investment of over Total R&D Spends (Capex + Opex) i
Slide 16: Delivered Robust Profitable Growth & Returns over the years
Delivered Robust Profitable Growth & Returns over the years ._. Caplin Point V ---------------------------------------------------- Laboratories Limited Total Revenue EBITDA PAT (INR Cr) 1,308 (INR Cr) 433 (INR Cr) 308 1,085 352 905 301 251 250 215 668 207 177 553 145 412 134 313 96 255 87 177 62 58
Slide 17: Content
._. Caplin Point ----------------------------------------------------------~v Laboratorieslimited Content 1 Q1FY23 Highlights 2 Understanding Caplin 3 Growth Engines of Caplin 4 Appendix Amaris Clinical - CRO Clinic, Chennai 17
Slide 18: Caplin's Growth Engines
Caplin’s Growth Engines 1m1ted Core business to grow at historical pace… 1 Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at above industry- average pace with margins expected to improve with increased branded generics business … with US Business
Slide 19: Core business to grow at historical pace…
01 | Core business to grow at historical pace… Overview Performance LATAM Operating Revenue from LATAM + Africa (INR Cr) No. 1 Indian player in Central America 1,147 Increased its LATAM footprint from two countries to 12 countries within a decade 976 Entry into Pharmacy sales through Healthcar
Slide 20: Caplin's Healthcare portal
Caplin’s Healthcare portal ._. Caplin Point V Laboratories Limited uso202K Monthly Average 2022 452sKUs Monthly Average 2022 20
Slide 21: … with US business to boost the overall growth…
02 | … with US business to boost the overall growth… ._. Caplin Point V ------------------------------------------------------------- Laboratories Limited Overview Injectable plant Inspection history Invested ~Rs.450 Crore in Capex and Opex for the 5 years since 2014 through Plant has undergone 3
Slide 22: “Capital Plus” partner for Caplin Steriles Ltd.
“Capital Plus” partner for Caplin Steriles Ltd. ._. Caplin Point V ------------------------ Laboratories Limited Transaction Structure Transaction Details Objective Increase R&D capabilities to include Complex Injectable and Ophthalmic products 8 EIGHT ROADS™ 00 portfolio and enhance capacities at
Slide 23: Market opportunity in US
Market opportunity in US ._. Caplin Point V ------------------------------------------------------------- Laboratories Limited ~ $4.9 Bn $670mn Market size of our products approved and under Overall market size of our products in Pipeline, under approval approval and approved Overall market opportun
Slide 24: … backed by enhanced value chain…
03 | … backed by enhanced value chain… ._. Caplin Point V ------------------------------------------------------------- Laboratories Limited Our strategic decisions which will help us in scaling up value chain Direct approach Forward integration Backward integration Setting up of CRO Plant to Portal
Slide 25: Amaris Clinical - CRO Division of Caplin Point
Amaris Clinical - CRO Division of Caplin Point Caplin Point Laboratories Limited Amaris Clinical – Highlights High level of data integrity Cost savings of 72-bed state of compliance through end to Capex of INR 29 ~50% the art facility end automation Cr. internally accrued Technologically advanced Co
Slide 26: … Strong balance sheet and…
04 | … Strong balance sheet and… ._. Caplin Point V ----------------------------------------------------------- Caplin’s strong balance sheet acts as a anchor for it’s vision of perceiving an ‘Invisible opportunity’ Laboratories Limited Receivable Days Total Capex (INR Cr) Fixed Asset Turnover Ratio
Slide 27: Content
Caplin Point --------------• Laboratories Limited Content 1 Q1FY23 Highlights 2 Understanding Caplin 3 Growth engines of Caplin 4 More about Caplin 4.1 Experienced and Visionary Board of Directors 4.2 Shareholder Information R&D centre 27
Slide 28: Experienced and Visionary Board of Directors
Experienced and Visionary Board of Directors ._. Caplin Point V ------------------------------------------------------------- Laboratories Limited Mr. C.C. Paarthipan Dr. Sridhar Ganesan Dr. K.C. John Chairman Managing Director Independent Director 30+ Years of experience in 35+ Years experience
Slide 29: Experienced and Visionary Board of Directors (cont'd)
Experienced and Visionary Board of Directors (cont’d) ._. Caplin Point V ------------------------------------------------------------- Laboratories Limited D Sathyanarayanan Dr. C K Gariyali, IAS Mr V Thirumalai R Viswanathan Independent Director Independent Director Independent Director Independent
Slide 30: Shareholder Information
Shareholder Information ._. Caplin Point V --------------------------------------------------------------- Laboratories Limited Caplin Shareholding as on 30th June 2022 Share Information (as on 30th June 2022) NSE Ticker CAPLIPOINT Others BSE Ticker 524742 27.98% Market Cap (INR Cr) 5,385 % free-flo
Slide 31: Our Products
Our Products Caplin Point Laboratones · Limited . 31
Slide 32: Caplin Point Laboratories Limited
Caplin Point I Laboratories Limited II ~ Investor Relations at Caplin • Mr G Venkatram - ,.. investor@caplinpoint.net Ernst & Young Rahul Thakur rahul.thakur@in.ey.com ., I , CIN: L24231TN1990PLC019053 | ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET 3SE 524742 NSE CAPLIPOINT ©2018, Capl